Raloxifene Stimulates Estrogen Signaling to Protect Against Age- and Sex-Related Intervertebral Disc Degeneration in Mice

Estrogen agonist raloxifene is an FDA-approved treatment of osteoporosis in postmenopausal women, which may also be a promising prophylactic for painful intervertebral disc (IVD) degeneration. Here, we hypothesized that 1) aging and biological sex contribute to IVD degeneration by reducing estrogen...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhadouria, Neharika, Berman, Alycia G., Wallace, Joseph M., Holguin, Nilsson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Bioengineering and Biotechnology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404526/
https://www.ncbi.nlm.nih.gov/pubmed/36032728
http://dx.doi.org/10.3389/fbioe.2022.924918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404526/
https://www.ncbi.nlm.nih.gov/pubmed/36032728
http://dx.doi.org/10.3389/fbioe.2022.924918

Ejemplares similares